New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors
- None.
- None.
Insights
The strategic formation and launch of Eyconis, Inc. by Ascendis Pharma in collaboration with Frazier Life Sciences represents a significant move within the biopharmaceutical industry, particularly in the ophthalmology sub-sector. This joint venture leverages Ascendis Pharma's proprietary TransCon technology to address a range of ocular diseases, which has the potential to revolutionize treatment paradigms in conditions like wet age-related macular degeneration (AMD) and diabetic macular edema (DME). The technology's promise for long-acting delivery of biologics could position Eyconis as a frontrunner in developing next-generation therapies.
The equity stake and milestone payments agreement, which could total up to $248 million, plus royalties, underscores a substantial financial opportunity for Ascendis. This deal structure is conducive to risk-sharing and aligns the interests of both entities. For investors, this initiative could enhance Ascendis Pharma's revenue streams, diversify its portfolio and mitigate the concentration risk associated with its endocrinology rare disease focus. The inclusion of seasoned industry executives and experts on Eyconis' board and management team further solidifies the company's strategic direction and operational potential.
From a financial perspective, the creation of Eyconis, Inc. and the associated licensing and equity arrangements present a multifaceted investment opportunity. The agreement's structure, with development, regulatory and sales milestone payments, plus royalties on global net sales, provides Ascendis Pharma with a non-dilutive funding mechanism that preserves capital while potentially delivering significant returns. The presence of a strong investor syndicate, including RA Capital Management, venBio and HealthQuest Capital, is indicative of the high confidence in the market potential of TransCon ophthalmology products.
While the immediate financial impact on Ascendis Pharma's balance sheet may be limited to the equity position's value, the long-term potential for milestone payments and royalties could be substantial, contingent upon successful product development and commercialization. This strategic move could be perceived positively by the market, as it demonstrates Ascendis Pharma's ability to monetize its technology platform beyond its core business, potentially leading to an increase in shareholder value over time.
The medical significance of Eyconis' focus on retinal diseases cannot be overstated. The prevalence of conditions such as AMD, DME, RVO and GA, coupled with the limitations of current treatment options, underscores a substantial unmet need in the ophthalmology field. TransCon technology's ability to provide long-acting delivery of biologics may offer a considerable advantage over existing therapies, which often require frequent and invasive administration. This technology could improve patient compliance and outcomes, representing a breakthrough in the management of retinal diseases.
Given the complexity of ophthalmology product development, the expertise of the leadership team, including Dr. Emmett Cunningham and Oliver Boris Stauch, will be crucial in navigating clinical trials and regulatory pathways. The potential benefits for patients and the healthcare system are significant, as innovative treatments could reduce the burden of retinal diseases and improve the quality of life for millions of patients worldwide. The scientific community will be watching closely as Eyconis progresses through the development pipeline, looking for evidence of efficacy and safety that could redefine standard care practices.
COPENHAGEN, Denmark, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the formation and launch with Frazier Life Sciences of Eyconis, Inc., a separate company created to develop, manufacture, and commercialize TransCon ophthalmology assets globally, together with an investor syndicate that includes Frazier, RA Capital Management, venBio, and HealthQuest Capital.
Ascendis Pharma has granted Eyconis exclusive rights to develop and commercialize TransCon ophthalmology products globally and received an equity position in the newly formed company. In addition, Ascendis will be eligible to receive development, regulatory, and sales milestone payments of up to
Eyconis is led by ophthalmology industry veteran, Emmett Cunningham, M.D., Ph.D., MPH, Senior Partner at HealthQuest Capital, who joins Eyconis as Executive Chairman, and experienced biopharmaceutical executive Oliver Boris Stauch, who joins Eyconis as Chief Operating Officer after serving previously as Head of Ophthalmology at Ascendis Pharma.
“The opportunity for Eyconis is tremendous, given the acknowledged need for improved ophthalmology treatments, particularly in wet age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO) and geographic atrophy (GA),” said Dr. Emmett Cunningham, Eyconis' Executive Chairman. “We believe the TransCon technology platform will be the first to achieve long-acting and effective delivery of multiple clinically validated biologics - which together constitute the most commonly used therapies for the major causes of retinal blindness. With the expertise of the Eyconis team and access to TransCon technology, we believe Eyconis is well-positioned to develop innovative, best-in-class therapies for retinal disease.”
In addition to Dr. Cunningham, Daniel Estes, Ph.D., and Anna Chen, Ph.D., from Frazier, Conrad Wang, M.D., from HealthQuest Capital, and Yvonne Yamanaka, Ph.D., from venBio have joined the board in connection with the financing. Ascendis has the right to designate one individual to the board.
“Through partnership with experts who have significant knowledge and deep experience in ophthalmology, we have an opportunity to apply our unique TransCon technology platform to develop new treatment options to address large unmet medical needs beyond our core focus in endocrinology rare disease,” said Jan Mikkelsen, Ascendis Pharma’s President and Chief Executive Officer. “The formation of Eyconis is a great example of how we are working to leverage the broad potential of TransCon in new therapeutic areas to create value for patients, shareholders and society.”
About Ascendis Pharma A/S
Ascendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by its core values of patients, science and passion, the company uses its TransCon technologies to create new and potentially best-in-class therapies. Ascendis is headquartered in Copenhagen, Denmark and has additional facilities in Germany and the United States. Please visit http://ascendispharma.com to learn more.
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) Eyconis’ ability to develop, manufacture, and commercialize TransCon ophthalmology assets globally with an investor syndicate, (ii) Ascendis’ eligibility to receive development, regulatory, and sales milestone payments and royalties and the amounts thereof, (iii) Ascendis’ expectation that Eyconis will initially be based in Redwood City, California and certain Ascendis employees will join the newly formed company, (iv) the TransCon platform’s ability to achieve long-acting and effective delivery of multiple clinically validated biologics, (v) Eyconis’ ability to develop innovative, best-in-class therapies for retinal disease, (vi) Ascendis’ ability to apply its TransCon technology platform to develop new treatment options to address large unmet medical needs beyond its core focus in endocrinology rare disease, (vii) Ascendis’ ability to leverage TransCon in new therapeutic areas, (viii) Ascendis’ ability to apply its platform technology to build a leading, fully integrated biopharma company and (ix) Ascendis’ use of its TransCon technologies to create new and potentially best-in-class therapies. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: dependence on third party manufacturers, distributors and service providers for Ascendis’ products and product candidates; unforeseen safety or efficacy results in Ascendis’ development programs or on-market products; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen expenses related to Ascendis’ development programs; unforeseen selling, general and administrative expenses, other research and development expenses and Ascendis’ business generally; delays in the development of its programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; Ascendis’ ability to obtain additional funding, if needed, to support its business activities; the impact of international economic, political, legal, compliance, social and business factors, including inflation, the effects on its business from the worldwide COVID-19 pandemic and ongoing conflicts such as that in the region surrounding Ukraine and Russia. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 16, 2023 and Ascendis’ other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.
Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, and TransCon are trademarks owned by the Ascendis Pharma group. © January 2024 Ascendis Pharma A/S.
| Investor Contacts: | Media Contact: |
| Tim Lee | Melinda Baker |
| Ascendis Pharma | Ascendis Pharma |
| +1 (650) 374-6343 | +1 (650) 709-8875 |
| tle@ascendispharma.com | media@ascendispharma.com |
| ir@ascendispharma.com | |
| Patti Bank | |
| ICR Westwicke | |
| +1 (415) 513-1284 | |
| patti.bank@westwicke.com |
FAQ
What is the ticker symbol for Ascendis Pharma A/S?
What is the purpose of forming Eyconis, Inc.?
Who are the investors in Eyconis, Inc.?
What are the potential milestone payments for Ascendis Pharma A/S?
Who is leading Eyconis, Inc.?
